Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

610 ARTÍCULOS , VIENDO DEL 496 AL 510

Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment

Andreozzi E, Yagi T, Wildsmith K, Rawal S, Horie K, Boyd P, Takahashi E, Barthélemy NR, Aluri J, Charil A, Reilhac A, Gordon BA, Flores S, Verbel D, Sauter N, Benzinger TLS, McDade E, Mummery C; Dominantly Inherited Alzheimer Network (DIAN); Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU); Zhou J, Bateman RJ, Reyderman L.

Alzheimers Res Ther. 2026 Apr 10;18(1):87. doi: 10.1186/s13195-026-02047-y.

Digital biomarkers in early Alzheimer's disease from wearable or portable technology: A scoping review

Gramkow MH, Gleerup HSC, Simonsen AH, Waldemar G, Frederiksen KS.

J Neurol Sci. 2026 Feb 15;481:125734. doi: 10.1016/j.jns.2026.125734. Epub 2026 Jan 6.

Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers

Bailey-Taylor MJ, Morrow P, Hendrix J, Galluzzi KE, Sharafsaleh G.

Clin Interv Aging. 2026 May 12;21:585263. doi: 10.2147/CIA.S585263. eCollection 2026.

A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA

Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL.

Lancet Neurol. 2026 Mar;25(3):268-278. doi: 10.1016/S1474-4422(25)00483-1.

Connecting the Dots: Neurobiological Interplay Between Type 2 Diabetes and Alzheimer's Disease

Foncea-Bitrán A, Barros-Osorio C, Arriaza F, Ramírez-López C, Ruiz LM, Barreto M, Ortiz FC, Cornejo F, Gómez GI.

Int J Mol Sci. 2026 Apr 2;27(7):3225. doi: 10.3390/ijms27073225.

Should all MCI with Alzheimer's biological diagnosis receive anti-amyloid therapy?

Rossini PM, Pappalettera C.

Cell Death Dis. 2026 Feb 10;17(1):212. doi: 10.1038/s41419-026-08456-z.

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis

Wilson JM, Dage JL, Qian HR, Irelan CL, Crowder HS, Duffin KL, Mintun M, Brooks DA, Gerstein HC, Bethel MA.

Alzheimers Dement. 2026 Apr;22(4):e71391. doi: 10.1002/alz.71391.

Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study

Liao W, Yu Q, Chen B, Chen H, Zou L, Xie H, Chen H, Wang C, Li Y, Gao X, Guo H, Yang Y, She Z, Zeng Q, Zhang Z, Li G, Feng S, Lin H, Ouyang J, Liang J, Ao W, Zeng Q, Liu Z, Weng H, Huang H, Zhu F, Liu R, Wang Y, Yu D, Li X, Mai Y, Jiang S, Tu Y, Li Z, Liu J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2026 Mar;22(3):e71231. doi: 10.1002/alz.71231.

APOE4 and cognition in intracranial atherosclerosis: beyond Alzheimer's pathology

Cheng A, Zou Y, Liu L, Wang H, Ai Z, Wu S, Si Q, Liu Y, Zhou H, Guo H, Yu Q, Wang Z, Li M, Liu C, Xu W.

Alzheimers Dement. 2026 Feb;22(2):e71087. doi: 10.1002/alz.71087.

Disease modifying treatments for Alzheimer's disease: Clinician perspectives

Pennington C, Apurva P, Chen A, Duncan A, Mackay G, Masters H, Paramore K, Russ T, Skinner H, Zeidler M.

J Alzheimers Dis. 2026 May;111(1):125-131. doi: 10.1177/13872877261429859. Epub 2026 Mar 25.

Biomarkers for Alzheimer's disease and mild cognitive impairment: Recent advances in task-based EEG

Tripanpitak K, Wolf A, Kapitonova M, Umeda S, Ball T, Otake-Matsuura M.

J Alzheimers Dis. 2026 Mar;110(1):58-73. doi: 10.1177/13872877251413700. Epub 2026 Feb 4.

Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis

Malek-Ahmadi M, Sharma S, Stipho F, Denkinger M, Singh A, Brum WS, Ashton NJ.

JAMA Neurol. 2026 Jan 1;83(1):13-19. doi: 10.1001/jamaneurol.2025.4721.

Five-Year Cognitive Trajectories in Individuals with Mild Cognitive Impairment and Mild Dementia: Associations with Attendance in a Multimodal Day-Care Program

Nemoto M, Nemoto K, Ota M, Sasai H, Midorikawa H, Sekine A, Kitabatake A, Arai T.

Dement Geriatr Cogn Disord. 2026;55(3):223-232. doi: 10.1159/000548680. Epub 2025 Sep 29.

Clinical validation of an aggregate learning ratio from the neuropsychological assessment battery

Hall MG, Wollman SC, Haines ME, Katschke JL, Boyle MA, Richardson HK, Hammers DB.

Appl Neuropsychol Adult. 2026 Jan-Feb;33(1):55-64. doi: 10.1080/23279095.2024.2329974. Epub 2024 Mar 25.

The DDQ-30, a new naming-from-definition test: Normative data for the adult French-Quebec population and validation study in mild cognitive impairment and Alzheimer's disease

Macoir J, Febbrari R, Fiset N, Mulet-Perreault H, Laforce R, Hudon C.

Appl Neuropsychol Adult. 2026 Jan-Feb;33(1):73-83. doi: 10.1080/23279095.2024.2333327. Epub 2024 Mar 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias